API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Updates are based on more than five years of Phase 3 iNNOVATE final analysis data, which demonstrated IMBRUVICA plus rituximab significantly prolonged progression-free survival (PFS) versus rituximab alone in adults with WM.
Lead Product(s): Ibrutinib,Rituximab
Therapeutic Area: Oncology Product Name: Imbruvica
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
Details:
Phase 3 MURANO trial shows median progression-free survival of 53.6 months in previously treated CLL patients taking VENCLEXTA/VENCLYXTO in combination with rituximab Vs. 17.0 months in patients taking bendamustine plus rituximab after three years or more off treatment.
Lead Product(s): Venetoclax,Rituximab
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2020
Details:
Submission is based on results of more than five years of follow-up data from the Phase 3 iNNOVATE clinical trial evaluating IMBRUVICA in combination with rituximab for patients with WM. This is the longest follow-up data available for a BTK inhibitor in WM.
Lead Product(s): Ibrutinib,Rituximab
Therapeutic Area: Oncology Product Name: Imbruvica
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
Details:
DRL_RI is being developed as a biosimilar of Rituxan/MabThera (rituximab), a CD20 directed cytolytic antibody for various indications including treatment of adult patients with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, and pemphigus vulgaris.
Lead Product(s): Rituximab
Therapeutic Area: Immunology Product Name: DRL_RI
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2023
Details:
DRL_RI is being developed as a biosimilar of rituximab, CD20 directed cytolytic antibody for various indications including treatment of adult patients with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, pemphigus vulgaris etc.
Lead Product(s): Rituximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
PTG-007, a treg cell therapy, in combination with rituximab, a CD20 inhibitor, is being investigated in a phase 1/2 trial for the treatment of type-1 diabetes.
Lead Product(s): PTG-007,Rituximab
Therapeutic Area: Endocrinology Product Name: PTG-007
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2024
Details:
Calquence (acalabrutinib) is a next-generation, selective inhibitor of bruton’s tyrosine kinase (BTK). It is being evaluated for the treatment of mantle cell lymphoma in adults.
Lead Product(s): Acalabrutinib,Bendamustine Hydrochloride,Rituximab
Therapeutic Area: Oncology Product Name: Calquence
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Acerta Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2024
Details:
Adcetris (brentuximab vedotin) is a CD30 inhibitor, which is being evaluated in combination with lenalidomide and rituximab for the treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Lead Product(s): Brentuximab Vedotin,Lenalidomide,Rituximab
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2024
Details:
Enterome lead product EO2463 is being evaluated in monotherapy and combination with lenalidomide and rituximab for the treatment of patients with indolent non-Hodgkin lymphoma.
Lead Product(s): EO2463,Lenalidomide,Rituximab
Therapeutic Area: Oncology Product Name: EO2463
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2024
Details:
FT522 is the Company’s CD19-targeted, iPSC-derived CAR NK cell product candidate that incorporates its novel alloimmune defense receptor (ADR) technology. It is being evaluated for the treatment of Relapsed/Refractory B-Cell Lymphoma.
Lead Product(s): FT522,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: FT522
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2024
Details:
Calquence (acalabrutinib) is a next-generation, selective inhibitor of bruton’s tyrosine kinase (BTK). It is being evaluated for the treatment of mantle cell lymphoma in adults.
Lead Product(s): Acalabrutinib,Bendamustine Hydrochloride,Rituximab
Therapeutic Area: Oncology Product Name: Calquence
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Acerta Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2024
Details:
Chidamide (Epidaza®) , an oral subtype-selective HDAC inhibitor, combined with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), has been officially approved by the NMPA for treatment of DLBCL with positive MYC and BCL2 expression.
Lead Product(s): Chidamide,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Epidaza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
EO2463, an innovative off-the-shelf immunotherapy candidate, is being assessed in early-stage clinical trials with patients for the treatment of follicular lymphoma and marginal zone lymphoma in combination with lenalidomide/rituximab.
Lead Product(s): EO2463,Lenalidomide,Rituximab
Therapeutic Area: Oncology Product Name: EO2463
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2024
Details:
ALX Oncology lead product candidate ALX148 (evorpacept) in combination with Rituximab and Lenalidomide is being evaluated with patients for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Lead Product(s): Evorpacept,Rituximab,Lenalidomide
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Details:
PTG-007, a treg cell therapy, in combination with rituximab, a CD20 inhibitor, is being investigated in a phase 1/2 trial for the treatment of type-1 diabetes.
Lead Product(s): PTG-007,Rituximab
Therapeutic Area: Endocrinology Product Name: PTG-007
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
Pfizer's Adcetris (brentuximab vedotin), CD30 inhibitor, which is being evaluated in Phase III clinical trial studies in combination with Lenalidomide and Rituximab for the treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Lead Product(s): Brentuximab Vedotin,Lenalidomide,Rituximab
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
BI-1206 is a first-in-class fully human monoclonal antibody (mAb) that targets FcγRIIB. It is being evaluated in combination with rituximab in patients with Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma.
Lead Product(s): BI-1206,Rituximab
Therapeutic Area: Oncology Product Name: BI-1206
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: CASI Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
AlloNK (AB-101) is an allogeneic NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies or NK cell engagers. in combination with rituximab or obinutuzumab for the treatment of lupus nephritis.
Lead Product(s): AB-101,Rituximab,Cyclophosphamide
Therapeutic Area: Nephrology Product Name: AlloNK
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
Rituxan (rituximab) is an anti-CD20 monoclonal antibody, which is now approved for the treatment of suppression and treatment of antibody-mediated rejection in organ transplantation.
Lead Product(s): Rituximab
Therapeutic Area: Immunology Product Name: Rituxan
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2023
Details:
ALE.F02 (Lixudebart Rituximab GlucoCorticoid) is a claudin 1 inhibitor antibody drug candidate, which is currently being evaluated for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rapidly progressive glomerulonephritis.
Lead Product(s): Lixudebart,Rituximab,GlucoCorticoid
Therapeutic Area: Immunology Product Name: ALE.F02
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
Rituxan (rituximab) is an anti-CD20 monoclonal antibody that specifically binds to CD20, a protein expressed on B cells, excluding hematopoietic stem cells and plasma cells, which is used for the treatment of Lupus Nephritis.
Lead Product(s): Rituximab
Therapeutic Area: Nephrology Product Name: Rituxan
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details:
AlloNK (AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with Combination with Rituximab in Lupus Nephritis.
Lead Product(s): AB-101,Rituximab
Therapeutic Area: Immunology Product Name: AlloNK
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
ADC Therapeutics' CD19-specific Antibody Drug Conjugate (ADC), Zynlonta (loncastuximab tesirine-lpyl) is FDA-approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more systemic therapies.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
Zynlonta (loncastuximab tesirine-lpyl), an antibody-drug conjugate (ADC) targeting CD19, is being developed in combination with rituximab in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
GEN3013 (epcoritamab-bysp) is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody® technology. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells, which is used for Diffuse Large B-cell Lymphoma.
Lead Product(s): Epcoritamab-bysp,Rituximab,Lenalidomide
Therapeutic Area: Oncology Product Name: GEN3013
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
Polivy® (polatuzumab vedotin-piiq) is a first-in-class anti-CD79b antibody-drug conjugate (ADC). It binds to cancer cells such as CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells.
Lead Product(s): Polatuzumab Vedotin-piiq,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2023
Details:
Tavneos (avacopan) is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a, blocking neutrophil activation and migration. Currently being developed for the treatment of ANCA-associated vasculitis.
Lead Product(s): Avacopan,Rituximab
Therapeutic Area: Rare Diseases and Disorders Product Name: Tavneos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
Polivy® (polatuzumab vedotin-piiq) is a first-in-class anti-CD79b antibody-drug conjugate (ADC). It binds to cancer cells such as CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells.
Lead Product(s): Polatuzumab Vedotin,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
Tavneos (avacopan) is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a, blocking neutrophil activation and migration. Currently being developed for the treatment of ANCA-associated vasculitis.
Lead Product(s): Avacopan,Rituximab
Therapeutic Area: Immunology Product Name: Tavneos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
Pirtobrutinib (LOXO-305), is an investigational, highly selective, reversible (non-covalent) inhibitor of Bruton's tyrosine kinase (BTK). Pirtobrutinib was developed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate.
Lead Product(s): Pirtobrutinib,Venetoclax,Rituximab
Therapeutic Area: Oncology Product Name: LOXO-305
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
The acquisition includes TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor that was approved by the U.S. FDA in October 2021 as an adjunctive therapy for adults with severe active ANCA-associated vasculitis.
Lead Product(s): Avacopan,Rituximab
Therapeutic Area: Immunology Product Name: Tavneos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 20, 2022
Details:
CYT-0851 is in a Phase 1/2 clinical trial as both a monotherapy and in combination with standard of care chemotherapy and has the potential to be a first-in-class MCT inhibitor. By impairing monocarboxylate transporter-mediated lactate transport, CYT-0851 disrupts glycolysis.
Lead Product(s): Rad51-IN-2,Rituximab,Bendamustine Hydrochloride
Therapeutic Area: Oncology Product Name: CYT-0851
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
AB-101, an ADCC enhancer NK-cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers. Artiva is currently advancing a Phase 1/2 of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas.
Lead Product(s): AB-101,Rituximab,Interleukin 2
Therapeutic Area: Oncology Product Name: AB-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
ZYNLONTA® (loncastuximab tesirine-lpyl) is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
The opinion is based on data from LOTIS-2, a large (n=145) Phase 2 multinational, single-arm clinical trial of ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory DLBCL following two or more prior lines of systemic therapy.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Swedish Orphan Biovitrum AB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2022
Details:
BI-1206, a first-in-class fully human monoclonal antibody (mAb) that targets FcγRIIB, in combination with rituximab in patients with relapsed/refractory Non-Hodgkin's Lymphoma (NHL).
Lead Product(s): BI1206,Rituximab
Therapeutic Area: Oncology Product Name: BI1206
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioInvent
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
TAVNEOS® (avacopan) is indicated as adjunctive treatment of adult patients with severe active ANCA-associated vasculitis (granulomatosis with polyangiitis) and microscopic polyangiitis [MPA] in combination with standard therapy including glucocorticoids.
Lead Product(s): Avacopan,Rituximab
Therapeutic Area: Immunology Product Name: Tavneos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2022
Details:
Polivy® intravenous infusion 30 mg and 140 mg [generic name: polatuzumab vedotin (genetical recombination)] for an additional indication of treatment of patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Lead Product(s): Polatuzumab Vedotin,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2022
Details:
Tavneos® (avacopan) is an orally administered small molecule that is a selective inhibitor of the complement C5a receptor C5aR1,reduces the ability of those cells to do damage in response to C5a activation.
Lead Product(s): Avacopan,Rituximab,Cyclophosphamide
Therapeutic Area: Immunology Product Name: Tavneos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL).
Lead Product(s): Polatuzumab Vedotin,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Polivy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2022
Details:
mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (rituximab), through its in-house biosimilars programs and through its investment in mAbxience, Fresenius expects rapid growth in biopharmaceutical market.
Lead Product(s): Rituximab
Therapeutic Area: Oncology Product Name: Novex
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Fresenius Kabi AG
Deal Size: $553.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition August 01, 2022
Details:
ZYNLONTA® (loncastuximab tesirine-lpyl), is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
ME-401 (zandelisib), a selective PI3Kδ inhibitor, is an investigational cancer treatment being developed as an oral, once-daily, potential therapeutic option for patients with B-cell malignancies.
Lead Product(s): Zandelisib,Rituximab
Therapeutic Area: Oncology Product Name: ME-401
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kyowa Kirin
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers.
Lead Product(s): EO2463,Rituximab,Lenalidomide
Therapeutic Area: Oncology Product Name: EO2463
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
ZYNLONTA® (loncastuximab tesirine-lpyl) is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
Lead Product(s): Loncastuximab Tesirine,Rituximab
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Overland Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2022
Details:
Rituxan (rituximab) is an anti-CD20 monoclonal antibody that specifically binds to CD20, a protein expressed on B cells, excluding stem cells and plasma cells. It attacks target B cells using the immune system equipped with the human body, and damages cells.
Lead Product(s): Rituximab
Therapeutic Area: Rare Diseases and Disorders Product Name: Rituxan
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2022
Details:
ME-401 (zandelisib), an orally administered investigational phosphatidylinositol 3- kinase delta ("PI3Kδ") inhibitor in clinical development for the treatment of B-cell malignancies
Lead Product(s): Zandelisib,Rituximab
Therapeutic Area: Oncology Product Name: ME-401
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kyowa Kirin
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
RIABNI (rituximab-arrx), a biosimilar to Rituxan, CD20-directed cytolytic antibody, was proven to be highly similar to, with no clinically meaningful differences in safety or efficacy from, based on totality of evidence.
Lead Product(s): Rituximab
Therapeutic Area: Immunology Product Name: Riabni
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Data for CYT-0851 show that the drug has performed well in cancer patients: it has desirable pharmacologic properties with an estimated half-life of three days, dose proportional exposure, and a dose dependent, predictable, and favorable safety profile.
Lead Product(s): Rad51-IN-2,Rituximab,Bendamustine Hydrochloride
Therapeutic Area: Oncology Product Name: CYT-0851
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2022
Details:
A phase 2 study evaluated the efficacy of Debio 1562 (naratuximab emtansine), an anti-CD37 ADC, in combination with rituximab, in patients with R/R DLBCL. Deep learning models were used to extract spatial features from digitized slides stained with CD37 and CD20.
Lead Product(s): Naratuximab Emtansine,Rituximab
Therapeutic Area: Oncology Product Name: Debio 1562
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022